MedTrace Logo

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

NCT04552509 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2025-07-22

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatment technique used to treat tumors. Despite the word "surgery" in the name, the technology does not remove the tumor with a surgical knife. Instead, a focused, high-intensity beam of radiation targets the tumor, while minimizing dose to surrounding normal healthy tissue.

Conditions

Interventions

RADIATION

Stereotactic Body Radiotherapy

Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)

Sponsors & Collaborators

  • Linda Chan, MD

    lead OTHER

Principal Investigators

  • Linda Chan, MD · Memorial Health Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-05
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552509 on ClinicalTrials.gov